RxDoctor Payments Data

Anthony Rosa, MD

Gastroenterology · Bala Cynwyd, PANPI 1245294941

Payments from drug & device makers

$11,495in general payments, 2019–2025

Across 654 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Gilead$573
  • Pfizer$500
  • plus $3K from 25 others

What the payments were for

  • Consulting fees$150%
  • Food & beverage$11,446100%
  • Education$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,495 in reported general payments places this provider in the 75th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$77,511
Medicare patients
309
Services billed
624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase33$59,989
LinzessLinaclotide30$19,859
Budesonide ErBudesonide13$16,203
Dexlansoprazole DrDexlansoprazole28$8,289
Mesalamine28$8,036
Mesalamine ErMesalamine19$6,161
Mesalamine DrMesalamine17$6,128
Ursodiol21$2,646
Sucralfate12$2,346
Pantoprazole Sodium178$2,217
Omeprazole151$1,326
Dicyclomine Hcl42$1,214
Esomeprazole Magnesium35$1,071
Famotidine72$968
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine32$933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$3,059$79,84863 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Bala Cynwyd

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →